UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Accretion of the Earth and segregation of its core

Nature, 2006-06, Vol.441 (7095), p.825-833

2006

Volltextzugriff (PDF)

Late Accretion on the Earliest Planetesimals Revealed by the Highly Siderophile Elements

Science (American Association for the Advancement of Science), 2012-04, Vol.336 (6077), p.72-75

2012

Volltextzugriff (PDF)

The development of a growth regime map for a novel reverse-phase wet granulation process

International journal of pharmaceutics, 2016-10, Vol.512 (1), p.224-233

2016

Volltextzugriff (PDF)

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9514-9514

2020

Volltextzugriff (PDF)

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3004-3004

2017

Volltextzugriff (PDF)

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3001-3001

2016

Volltextzugriff (PDF)

The Impact of Social History on the Development of Alzheimer’s Disease (P14-6.007)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8010-8010

2014

Volltextzugriff (PDF)

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2524-2524

2013

Volltextzugriff (PDF)

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2616-2616

2021

Volltextzugriff (PDF)

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

Journal of clinical oncology, 2020-06, Vol.38 (18_suppl), p.LBA5-LBA5

2020

Volltextzugriff (PDF)

A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS9084-TPS9084

2020

Volltextzugriff (PDF)

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21682-e21682

2020

Volltextzugriff (PDF)

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9068-9068

2021

Volltextzugriff (PDF)

The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9059-9059

2021

Volltextzugriff (PDF)

EGFR-mutation detection in VTX-1-enriched CTCs, ctDNA, and comparison to tumor in patients with non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20525-e20525

2017

Volltextzugriff (PDF)

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9023-9023

2019

Volltextzugriff (PDF)

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3003-3003

2020

Volltextzugriff (PDF)

Phase I trial of in situ vaccination with autologous CCL21 -modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS9135-TPS9135

2021

Volltextzugriff (PDF)

Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8564-8564

2021

Volltextzugriff (PDF)

Nivolumab (nivo) + nab -paclitaxel ( nab -P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9095-9095

2017

Volltextzugriff (PDF)

Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with EGFR-mutated NSCLC

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9031-9031

2017

Volltextzugriff (PDF)

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3011-3011

2020

Volltextzugriff (PDF)

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9002-9002

2020

Volltextzugriff (PDF)

1 – 25 von 317

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(312)
Mit Volltextzugriff
(257)

Publikationsform

Artikel
(317)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Accretion of the Earth and segregation of its core

Late Accretion on the Earliest Planetesimals Revealed by the Highly Siderophile Elements

The development of a growth regime map for a novel reverse-phase wet granulation process

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients

Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients

CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC

The Impact of Social History on the Development of Alzheimer’s Disease (P14-6.007)

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06)

A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)

Neratinib efficacy in a subgroup of patients with EGFR exon 18 - mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial

The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study

EGFR-mutation detection in VTX-1-enriched CTCs, ctDNA, and comparison to tumor in patients with non-small cell lung cancer (NSCLC)

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer

Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Phase I trial of in situ vaccination with autologous CCL21 -modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ)

Nivolumab (nivo) + nab -paclitaxel ( nab -P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study

Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with EGFR-mutated NSCLC

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study

Aktive Filter

Suchergebnisse filtern